Abstract. Several clinical trials have demonstrated the benefit of adding pertuzumab to trastuzumab plus neoadjuvant chemotherapy in the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The comparison of outcomes between nonrandomized groups of patients who received similar treatments in routine practice remains difficult. The present study aimed to evaluate the pathological complete response (pCR) rates achieved with pertuzumab among patients in routine clinical care in Peru using real-world data. The definition of pCR used was the absence of residual invasive cancer from the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy. A total of 44 patients with non-metastatic HER2-positive breast cancer (stages II and III) treated with pertuzumab in the neoadjuvant setting and who underwent surgery at three private clinics in Lima (Peru) were retrospectively evaluated. The pCR was the efficacy endpoint and it was determined and compared with the results from other clinical trials. Furthermore, safety data were described. The median age was 44 years (interquartile range, 39.5-50.5 years) and 65.9% of patients were premenopausal. Regarding the clinical stage, 56.8% were IIA/IIB and 36.4% were IIIA/IIIB/IIC. All treatment schemes included concurrent trastuzumab. The patients’ treatment comprised neoadjuvant therapy of docetaxel/trastuzumab/pertuzumab (THP) with a median of 4 cycles in 30 patients (68.2%) or docetaxel/trastuzumab/pertuzumab/carboplatin (THPCarb) with a median of 6 cycles in 14 patients (31.8%). In total, 70.5% of patients experienced pCR; among hormone receptor-negative cases, 75.0% achieved pCR and in tumors expressing hormone receptors, the rate of pCR was 66.7%. Of those patients subjected to neoadjuvant treatment with THP, 66.7% (20/30) achieved pCR, whereas 78.6% (11/14) of patients who received THPCarb had a pCR. The incidence of drug-related adverse events was 59.1% and in none of the patients, administration was discontinued due to toxicity. The present results of Peruvian patients with HER2 breast cancer treated according to clinical routine demonstrated that dual blockade of HER2 with trastuzumab and pertuzumab in the neoadjuvant setting achieved high rates of pCR even in hormone receptor-positive patients. These results are consistent with those of randomized controlled trials, with a good safety profile.

Introduction

Human epidermal growth factor receptor 2 (HER2) overexpression (or HER2-positive) is present in ~30% of breast tumors and is known to be associated with poor prognosis (1). In Peru, two independent studies based in hospital registries in two different referral cancer centers reported a frequency of HER2-positive breast tumors of 19.8 and 29.4%, respectively (2,3), which are similar to frequencies reported elsewhere. The use of anti-HER2 monoclonal antibody in addition to chemotherapy produced an improvement in survival compared with chemotherapy alone, changing the clinical outcomes of this type of breast tumor (4). The first one of these anti-HER2 monoclonal antibodies, trastuzumab, has higher pathological complete response (pCR) rates when used concurrently with anthracyclines compared to its non-concurrent use, as indicated in a meta-analysis of 5 studies [odds ratio (OR): 2.36; 95% CI: 1.69-3.30] (5).

Pertuzumab was Food and Drug Administration (FDA)-approved for use as a neoadjuvant treatment after the results of the NEOSPHERE and TRYPHAENA trials (6). Although trastuzumab and pertuzumab share the same target, these antibodies lack pharmacokinetic drug-drug interactions and they have complementary mechanisms to increase the anti-proliferative activity and as a consequence...
improve the clinical prognosis (7). One systematic review on stage I-III HER2-positive breast cancer indicated a higher rate of pCR among patients with pertuzumab and trastuzumab compared with those on trastuzumab alone (OR=1.33; 95% CI, 1.08-1.63) (8). Regarding its safety, treatment with trastuzumab and pertuzumab had a manageable toxicity profile with rare events of significant toxicity even in combination with anthracyclines (9). In addition, this combination represents an attractive cost-effective therapy for patients with HER2-positive early breast cancer (10).

After the therapeutic success of phase II trials on neoadjuvant therapy, the FDA approved pertuzumab, and since then, numerous phase III studies have been performed; in addition, an increasing number of studies on pertuzumab with real-world data were performed with the aim to evaluate whether the results obtained in trials are similar to those from routine clinical practice (11-14). However, evidence from low- and middle-income countries (LMICs) is currently lacking, and hence, the present study was implemented to estimate the rates of pCR in patients with HER2-positive non-metastatic breast cancer treated according to clinical routine in Peru with pertuzumab with neoadjuvant chemotherapy.

Materials and methods
Study design. NeoHer is a multicenter observational study, which aims to evaluate the use of pertuzumab in addition to neoadjuvant chemotherapy and concomitant trastuzumab in patients with HER2-positive non-metastatic breast cancer treated in the clinical routine. The independent Institutional Review Board (IRB) of Via Libre (Lima, Peru) approved the protocol of the present study. This IRB is properly accredited and registered by the National Institute of Health of Peru.

Patients. The clinical records of patients with breast cancer from three private clinics in Lima (Peru), namely Oncosalud-AUNA, Clinica Internacional and Aliada, between January 2014 and December 2016, were retrospectively reviewed. The inclusion criteria were as follows: Female patients aged ≥18 years with a pathological diagnosis of non-metastatic HER2+ breast cancer (regardless of hormone receptor status), treatment with any regimen that included pertuzumab in addition to neoadjuvant chemotherapy and trastuzumab, and patients who were subjected to breast surgery after neoadjuvant treatment. Patients with concomitant cancer treatment or a history of another malignancy were excluded.

The assessment of the estrogen receptor (ER), progesterone receptor (PR) and HER2 status was only performed in core biopsies and it was not centralized. All procedures were conducted according to local protocols following the American Society of Clinical Oncology/College of American Pathologists guidelines (15).

Study variables. The primary variable was the pCR status (classified as yes or no). pCR is defined as the absence of residual invasive cancer on H&E evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy [i.e., ypT0/Tis ypN0 in the current American Joint Committee on Cancer (AJCC) staging system], or as the absence of residual invasive and in situ

| Characteristic                  | Value                        |
|--------------------------------|------------------------------|
| Median age, years (IQR)         | 44.0 (39.5-50.5)             |
| Median BMI, kg/m² (IQR)         | 24.0 (21.9-28.8)             |
| Menopausal status               |                              |
| Premenopausal                   | 29 (65.9)                    |
| Postmenopausal                  | 15 (34.1)                    |
| Smoking status                  |                              |
| Non-smokers                     | 42 (94.4)                    |
| Smokers                         | 2 (4.6)                      |
| Family history                  |                              |
| No                              | 30 (68.2)                    |
| Yes                             | 14 (31.8)                    |
| Comorbidity                     |                              |
| No                              | 36 (81.8)                    |
| Yes                             | 8 (18.2)                     |
| Median tumor size, mm (IQR)     | 45.5 (38.8-60.0)             |

Values are expressed as n (%) unless otherwise specified. BMI, body mass index; IQR, interquartile range; min-max, minimum-maximum values; ER, estrogen receptor; PR, progesterone receptor; THP, docetaxel/trastuzumab/pertuzumab; THPCarb, docetaxel/trastuzumab/pertuzumab/carboplatin.
cancer on H&E evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy (i.e., ypT0 ypN0 in the current AJCC staging system) (16). The type of breast surgery was dependent on the mastologist’s decision based on local practice and the decision regarding axillary dissection was made according to the status of sentinel lymph node assessment.

Secondary variables included age at diagnosis, body mass index (BMI), smoking status, family history of breast cancer, comorbidities, regimen of neoadjuvant chemotherapy, type of surgery, treatment discontinuation, dose interruption, hormone receptor status, menopausal status, tumor size, tumor node metastasis (TNM by the AJCC staging system) and clinical stage, status of lymph nodes, histological type, histological grade and adverse events (AE) according to the Common Terminology Criteria for AE, v. 5.0 (17).

Statistical analysis. A descriptive analysis of the data was performed. A convenience sample was analyzed comprising cases treated with neoadjuvant pertuzumab during the study treatment. Analyses were performed with Stata 16.0 (StataCorp LP).

Results

Clinicopathological features. In total, 44 patients with HER2-positive breast cancer were identified during the study period and included in the present retrospective review. The median age was 44.0 years [interquartile range (IQR), 39.5-50.5 years] and the median BMI was 24.0 kg/m² (IQR, 21.9-28.8 kg/m²). In total, 15 patients (34.1%) were postmenopausal. The clinicopathological characteristics of the patients are provided in Table I.

Table II. Analysis of variables influencing the pCR in patients with human epidermal growth factor receptor 2-positive breast cancer treated with neoadjuvant pertuzumab.

| Characteristic                              | Residual disease | pCR                      |
|---------------------------------------------|------------------|--------------------------|
|                                             | THP (n=10)       | THPCarb (n=3)            | Total (n=13) | THP (n=20) | THPCarb (n=11) | Total (n=31) |
| Median tumor size, mm (IQR)                | 50.0 (30.0-100.0)| 46.0 (40.0-150.0)        | 46.0 (40.0-60.0) | 47.5 (40.0-60.0) | 36.1 (30.0-55.0) | 45 (35.0-60.0) |
| Median BMI, kg/m²                           | 24.0 (21.6-45.0) | 25.4 (21.9-27.2)         | 24.7 (21.9-28.5) | 23.3 (22.0-27.3) | 24.5 (23.0-30.7) | 23.9 (22.2-28.8) |
| T stage                                     | 4 (19.0)         | 1 (4.8)                  | 5 (23.8)      | 8 (38.1)   | 8 (38.1)       | 16 (76.2)     |
| T1/T2                                      | 6 (26.1)         | 2 (8.7)                  | 8 (34.8)      | 12 (52.2)  | 3 (13.0)       | 15 (65.2)     |
| N stage                                     |                  |                          |              |            |               |              |
| N0                                          | 4 (28.6)         | 0 (0.0)                  | 4 (28.6)      | 6 (42.9)   | 4 (28.6)       | 10 (71.4)     |
| N1/N2                                      | 6 (20.0)         | 3 (10.0)                 | 9 (30.0)      | 14 (46.7)  | 7 (23.3)       | 21 (70.0)     |
| Clinical stage                              |                  |                          |              |            |               |              |
| IIA/IIIB                                   | 7 (28.0)         | 1 (4.0)                  | 8 (32.0)      | 9 (36.0)   | 8 (32.0)       | 17 (68.0)     |
| IIIA/IIIB/IIIC                             | 2 (12.5)         | 2 (12.5)                 | 4 (25.0)      | 9 (56.3)   | 3 (18.8)       | 12 (75.0)     |
| Histology                                   |                  |                          |              |            |               |              |
| Ductal                                      | 10 (25.6)        | 2 (5.2)                  | 12 (30.8)     | 19 (48.7)  | 8 (20.5)       | 27 (69.2)     |
| Others (non-lobular)                        | 0 (0.0)          | 1 (20.0)                 | 1 (20.0)      | 1 (20.0)   | 3 (60.0)       | 4 (80.0)      |
| Histological grade                          |                  |                          |              |            |               |              |
| II                                           | 5 (25.0)         | 1 (5.0)                  | 6 (30.0)      | 10 (50.0)  | 4 (20.0)       | 14 (70.0)     |
| III                                          | 5 (21.7)         | 2 (8.7)                  | 7 (30.4)      | 9 (39.1)   | 7 (30.4)       | 16 (69.6)     |
| Hormone-receptor status                     |                  |                          |              |            |               |              |
| ER-positive and/or PR-positive               | 7 (29.1)         | 1 (4.2)                  | 8 (33.3)      | 8 (33.3)   | 8 (33.3)       | 16 (66.7)     |
| ER-negative and PR-negative                 | 3 (15.0)         | 2 (10.0)                 | 5 (25.0)      | 12 (60.0)  | 3 (15.0)       | 15 (75.0)     |

Values are expressed as n (%) unless otherwise specified. BMI, body mass index; IQR, interquartile range; ER, estrogen receptor; PR, progesterone receptor; THP, docetaxel/trastuzumab/pertuzumab; THPCarb, docetaxel/trastuzumab/pertuzumab/carboplatin; pCR, pathological complete response.
The median tumor size was 45.5 mm (IQR, 38.8-60.0 mm). Regarding tumor stage, the most frequent was T2 (45.4%; n=20) and in terms of regional lymph node stage, N1 was the most frequent (54.6%; n=24) (Table I). Patients with clinical stages IIA/IIIB were more frequent (56.8%; n=25) and three cases presented with inflammatory disease (6.8%). Furthermore, 88.6% (n=39) of tumors had ductal histology, and regarding grading, 45.4% (n=20) of cases had grade II tumors and 52.3% (n=23) grade III tumors. A total of 54.5% (n=24) of tumors had expression of hormonal receptors (Table I).

Treatments. All cases received pertuzumab concurrently with trastuzumab in different schemes as described in Table I. The most frequent scheme was neoadjuvant docetaxel/trastuzumab (THP; 68.2%, n=30). Of these patients, 3 were initiated with doxorubicin-based chemotherapy while awaiting approval of dual-HER2 treatment by the insurance company; however, after completion of this chemotherapy, they received the dual blockade. A total of 14 participants (31.8%) were treated with docetaxel/trastuzumab/pertuzumab/carboplatin (THPCarb) (Table I). Mastectomy was performed in 70.5% (n=31) of patients and 29.5% had breast-conserving surgery (n=13). A total of 31 patients (70.5%) achieved pCR; among the hormone receptor-negative cases, 75% achieved pCR and in tumors expressing hormone receptors, the pCR rate was 66.7% (Table II). Of those patients who received neoadjuvant treatment with THP, 66.7% achieved pCR, whereas in patients who received THPCarb, the pCR rate was 78.6%.

Safety of pertuzumab. Any AEs were experienced in 26 patients (59.1%). Among them, 88.5% (n=23) presented with grade 1 AEs, 61.5% (n=16) with grade 2 AEs and 26.9% (n=7) with grade 3 AEs. Diarrhea was the most frequent adverse event (36.4%; n=16), and of the affected patients, 93.8% (n=15) presented with diarrhea grade 1, 43.8% (n=7) with grade 2 and 31.3% (n=5) with grade 3. Nausea and vomiting were present in 31.8% (n=14) (Table III).

Discussion

The generation of real-world evidence in oncology provides a valuable tool to determine the performance of approved interventions in a setting different from clinical trials (18). The present study reported on the use of pertuzumab in patients treated in clinical routine in three private centers in Peru, where all patients received dual blockade of HER2 with combined treatment of pertuzumab and trastuzumab with concomitant chemotherapy. Higher rates of pCR (70.5%) in comparison with other studies performed in similar settings (even in clinical trials) were obtained. For instance, the NEOPSHERE study achieved a pCR rate of 45.8% with THP, compared with 29.0% of patients treated with a combination of trastuzumab plus docetaxel (19). Another study (TRYPHAENA) reported pCR rates of 63.6% in patients treated with THPCarb (Arm C) (20) (Table IV). A systematic review indicated that the combination of pertuzumab and trastuzumab in stage I-IIII HER2 positive had a higher pCR rate compared with the regimen without pertuzumab (OR=1.3; 95% CI: 1.1-1.6; n=1,448, 4 studies) (8).

Studies using routine clinical information from different settings described similar pCR rates to those reported in clinical trials: One study in Cleveland reported a 53% pCR in patients retrospectively identified in a cancer data registry (21); another at the Massachusetts General Hospital Cancer Center reviewed clinical information from 121 patients and reported a pCR of 63% with THPCarb (22). A recent multicentric study performed in patients from Germany indicated a pCR rate of 52.8% among those who used pertuzumab and trastuzumab, which was 22.6% higher compared with that in patients treated with trastuzumab only (23). Other important phase III studies are TRAIN-2 and KRISTINE: The first trial investigated whether the addition of anthracyclines is able to improve pCR compared to a carboplatin-taxane regimen (24). Patients were randomized to receive paclitaxel and carboplatin with trastuzumab and pertuzumab for nine cycles or an anthracycline-based regimen for three cycles, followed by THPCarb for six cycles. The proportion of patients with pCR (ypT0/is + ypN0) was 68% for the group without anthracycline and 67% for the group with anthracycline (P=0.95). The KRISTINE trial compared the efficacy of trastuzumab emtansine (T-DM1) plus pertuzumab, which did not comprise any systemic chemotherapy regimen, with docetaxel, carboplatin and trastuzumab plus pertuzumab (25). In this study, the proportion of patients with pCR (ypT0/is + ypN0) was lower with T-DM1 plus pertuzumab as compared with docetaxel, carboplatin and trastuzumab plus pertuzumab (44 vs. 56%, respectively; P=0.016).

The high rates of pCR obtained in the present study in contrast to those from other studies may be due to the heterogeneity in of HER2 patient populations and also differences in the definition of pCR, as indicated in Table III. Furthermore, the clinicopathological characteristics were different among
studies. For instance, compared with those in other previously published studies, the patients of the present study were younger and tumors were smaller (21,23‑25).

Regarding safety, the present study suggested that the combination of pertuzumab plus trastuzumab in neoadjuvant regimes has a manageable toxicity profile without any cardiac events registered. The safety of this combination has been extensively evaluated even in older patients without any important differences with regard to younger patients (26,27).

Certain studies have reported significantly lower rates of events of toxicity with the combination of pertuzumab and trastuzumab given with taxanes instead of with anthracyclines (22).

The search for biomarkers for pertuzumab is ongoing, and at present, the best predictor of response is molecular subtype HER2‑enriched status (as established by PAM50), where for these types of tumor, a pCR of 83.3% was achieved, in contrast to 46.3% for non-HER2‑enriched tumors (OR=5.8, 95% CI: 1.7‑19.4). Rates of pCR varied according to intrinsic subtype determined at baseline (28). The Blueprint platform was also able to identify patients who were HER2‑positive on immunohistochemistry that are more likely to respond to the combination of trastuzumab/pertuzumab (29) and other studies, such as the BERENICE trial, evaluating pertuzumab, trastuzumab and chemotherapy in patients with normal cardiac function, described similar results (30).

The present study has certain limitations, including a small sample size that increased the risk of chance in the present results, a retrospective design that increased the risk of information bias and unmeasured confounders, and heterogeneous regimens of coadjuvant chemotherapy treatment that make comparisons difficult in terms of adverse events and efficacy. However, the present study was the first, to the best of our knowledge, to evaluate and describe the use of pertuzumab in routine clinical use among Peruvian patients, with a high pCR.

### Table IV. Comparison of pCR in neoadjuvant trials including pertuzumab/trastuzumab with docetaxel + carboplatin.

| Characteristic | NeoHer (n=44) | NeoSpherea (n=107) | TRYPHAENAB (n=77) | KRISTINE (n=221) | TRAIN-2 (n=219) | JBCRG-20 (n=51) |
|---------------|--------------|--------------------|------------------|-----------------|----------------|----------------|
| Phase         | IV           | II                 | II               | III             | III            | II             |
| Median age, years (range) | 44.0 (25‑67) | 50 (28.0‑77.0) | 50.0 (30.0‑81.0) | 49 (41‑57) | 48 (43‑56) | 53.0 (28‑70) |
| Median tumor size, mm (IQR) | 45.5 (38.8‑60.0) | 55 (20‑150) | 50 (15‑200) | -               | -              | 27.0 (11‑58) |
| Regimen       | THP or THPCarb | TPH x 4          | TPH x 6         | TPH x 6        | TPH x 9       | TPH x 6        |
| Definition of pCR | ypT0/is+ypN0 | ypT0/is         | ypT0/is+ypN0     | ypT0/is+ypN0  | ypT0/is+ypN0 | ypT0/is+ypN0  |
| N stage       | N0           | N1                 | N2               | N3              |                |                |
|               | 14 (31.8)    | 24 (54.6)         | 6 (13.6)         | 0 (0)           |                |                |
|               | 31 (70.5)    | 49 (45.8)         | 22 (21)d         | 0 (0)           |                |                |
| Disease typee | Operable     | Locally advanced   | Inflammatory     |                |                |                |
|               | 32 (72.7)    | 8 (18.2)          | 3 (6.8)          | 24 (54.5)       |                |                |
|               | 65 (61)      | 32 (30)           | 10 (9)           | 50 (47)         |                |                |
|               | 49 (63.6)    | 24 (31.2)         | 4 (5.2)          | 40 (51.9)       |                |                |
| Hormone receptor status | ER‑positive and/or PR‑positive |           |                |                |
|               | 24 (54.5)    | 37 (48.1)         | 30 (58.8)        |                |                |
|               | 50 (47)      | 83 (37.6)         | 21 (41.2)        |                |                |
|               | 138 (62.4)   | 93 (42.0)         |                |                |                |
|               | 126 (58.0)   |                |                |                |                |

*aNeoSphere Arm Group B (Pertuzumab plus trastuzumab and docetaxel). bTRYPHAENNA Arm C (TCH + P X 6). cBased on 206 patients who were evaluable for the primary endpoint. If all non-evaluable patients were classified as no response, the percentage is 64%. dData missing for one patient (information from NeoSphere study). eOperable (T2‑3, N0‑1, M0), locally advanced (T2‑3, N2‑3, M0 or T4a‑c, any N, M0), inflammatory (T4d, any N, M0). Values are expressed as n (%) unless otherwise specified. IQR, interquartile range; ER, estrogen receptor; PR, progesterone receptor; THP, docetaxel/trastuzumab/pertuzumab; THPCarb, docetaxel/trastuzumab/pertuzumab/carboplatin; pCR, pathological complete response.
rate and an interesting safety profile; therefore, this real-world experience may help to refine and improve the potential use of pertuzumab in combination with trastuzumab in Peru and in similar settings at LMICs.

In conclusion, the neoadjuvant treatment of patients with HER2-positive non-metastatic breast cancer treated in the clinical routine in Peru with schemes based on the combination of trastuzumab and pertuzumab achieved a high rate of pCR even in tumors expressing hormone receptors, with a manageable profile of AEs. Further studies with larger samples and different populations are required to confirm these results.

Acknowledgements

Not applicable.

Funding

This research was funded by a research grant from Roche-Peru.

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors’ contributions

All authors contributed to the conception and design of the study. Material preparation and data collection were performed by SF, LR, CF, DV and HLG. The authenticity of raw data was verified by CF, DV and JAP. Data analysis was performed by DV and JAP. The first draft of the manuscript was written by JAP. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The IRB of Via Libre (Lima, Peru) approved the protocol of the present study. This study did not require any informed consent, as it was based on the review of medical charts only.

Patient consent for publication

Not applicable.

Competing interests

CF was an employee of Roche-Peru until mid-2019. Note that the funder of the study (Roche) participated in the design of the study. Data collection was performed by researchers working at the study sites. The data analysis was performed by an independent specialist paid by the funder. Finally, the corresponding author (HLG) prepared the initial draft of the report with support from a medical writer paid by the funder.

References

1. Ménard S, Tagliaube E, Campiglio M and Pupa SM: Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182: 150-162, 2000.

2. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, Suazo JF, Nciuosop SP, León M, de la Cruz MA and Vigil CE: Breast cancer classification according to immunohistochemistry markers: Subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer 10: 294-300, 2010.

3. Yábar A, Meléndez R, Muñoz S, Deneo H, Freire J, Domínguez V, Carrasco-Navarro RM, Díaz ME and Velarde-López RE: Effect of Ki-67 assessment in the distribution of breast cancer subtypes: Evaluation in a cohort of Latin American patients. Mol Clin Oncol 6: 503-509, 2017.

4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.

5. Wu YT, Xu Z, Zhang K, Wu JS, Li X, Arshad B, Li YC, Wang ZL, Li HY, Wu KN, et al: Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: A systematic review and meta-analysis. Ther Clin Risk Manag 14: 1789-1797, 2018.

6. Amiri-Kordestani L, Wedam S, Zhang L, Tang S, Tilley A, Ibrahim A, Justice R, Pazdur R and Cortazar P: First FDA approval of neoadjuvant therapy for breast cancer: Pertuzumab for the treatment of patients with HER2-positive breast cancer. Clin Cancer Res 20: 5359-5364, 2014.

7. Quartino AL, Li H, Jin JY, Wada DR, Benyunes MC, McNally V, Viganó L, Nijem I, Lum BL and Garg A: Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer. Cancer Chemother Pharmacol 79: 353-361, 2017.

8. Chen S, Liang Y, Feng Z and Wang M: Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: A systematic review and meta-analysis. BMC Cancer 19: 973, 2019.

9. van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, Kemper I, Smorenbch G, Stouthard JM, Lim SC, et al: Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. Breast 29: 153-159, 2016.

10. Attard CL, Pepper AN, Brown ST, Thompson MF, Thorresson PO, Yuenger S, Dent S, Paterson AH and Wells GA: Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab treatment for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada. J Med Econ 18: 173-188, 2015.

11. Krasniqi E, Pizzuti L, Barchiesi G, Sergi D, Carpano S, Botti C, Kayal R, Sanguineti G, Marchetti P, Botticelli A, et al: Impact of BMI on HER2+ metastatic breast cancer: Neoadjuvant treatment patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. J Cell Physiol 235: 7900-7910, 2020.

12. Matthews CM, Nymberg K, Berger M, Vargo CA, Dempsey J, Li J, Ramaswamy B, Reibolth R, Sardesai S, Wesołowski K, et al: Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience. J Oncol Pharm Prac 26: 572-579, 2020.

13. Rahardja S, Tan RYC, Sultana R, Leong FL and Lim E: Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2 metastatic breast cancer in Singapore: The National cancer centre Singapore experience. World J Clin Oncol 11: 143-151, 2020.

14. Booth CM, Karim S and Mackillop WJ: Real-world data: Towards achieving the achievable in cancer care. Nat Rev Clin Oncol 16: 312-325, 2019.

15. WolflAC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update. J Clin Oncol 31: 3997-4013, 2013.

16. Food and Drug Administration: Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval; Guidance for Industry; Availability. https://www.federalregister.gov/documents/2014/01/22/2014-23848/pathological-complete-response-in-neoadjuvant-treatment-of-high-risk-early-stage-breast-cancer-use. Accessed August 26, 2021.
17. National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE), v5.0, 2017.

18. Khozin S, Blumenthal GM and Pazdur R: Real-world data for clinical evidence generation in Oncology. J Natl Cancer Inst 109: dx187, 2017.

19. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawski E, de la Haba-Rodriguez J, Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13: 25-32, 2012.

20. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, et al: Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24: 2278-2284, 2013.

21. Tiwari SR, Mishra P, Raska P, Calhoun B, Abraham J, Moore H, Budd GT, Fanning A, Valente S, Stewart R, et al: Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer. Breast Cancer Res Treat 158: 189-193, 2016.

22. Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahm A, Brachet E, Specht M, et al: Efficacy and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat 172: 733-740, 2018.

23. Fasching PA, Hartkopf AD, Gass P, Häberle L, Akpolat-Basci L, Hein A, Volz B, Taran FA, Nabieva N, Pott B, et al: Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: A multicentric analysis. Breast Cancer Res Treat 173: 319-328, 2019.

24. van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, et al: Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19: 1630-1640, 2018.

25. Masuda N, Ohtani S, Takano T, Inoue K, Suzuki E, Nakamura R, Bando H, Ito Y, Ishida K, Yamanaka T, et al: A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCHHP), TCHHP followed by trastuzumab emtansine and pertuzumab (T-DM14P), and T-DM14P in HER2-positive primary breast cancer. Breast Cancer Res Treat 180: 135-146, 2020.

26. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S and Cortés J: Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 89: 27-35, 2018.

27. Hussain N, Said ASA and Khan Z: Safety assessment of neoadjuvant pertuzumab combined with trastuzumab in nonmetastatic HER2-positive breast cancer in postmenopausal elderly women of South Asia. Int J Breast Cancer 2018: 6106041, 2018.

28. Gaviá J, Oliveira M, Pascual T, Perez-Garcia J, González X, Canes J, Paré L, Calvo I, Ciruelos E, Muñoz M, et al: Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): An open-label, single-group, multicenter, phase 2 trial. BMC Med 17: 8, 2019.

29. Beitsch P, Whitworth P, Baron P, Rotkis MC, Mislowsky AM, Richards PD, Murray MK, Pellicane JV, Dul CL, Nash CH, et al: Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens in HER2-positive primary breast cancer: A cardiac safety study (Opti-HER HEART): A phase II, open-label, single-group, multicenter, phase 2 trial. Ann Surg Oncol 24: 2539-2546, 2017.

30. Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, et al: Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): A phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 29: 646-653, 2018.

31. Garrison LP Jr, Babigumira J, Tournier C, Goertz HP, Lubinga SJ and Perez EA: Cost-effectiveness analysis of pertuzumab with trastuzumab and chemotherapy compared to trastuzumab and chemotherapy in the adjuvant treatment of HER2-positive breast cancer in the United States. Value Health 22: 408-415, 2019.

32. Carvalho AC, Vasconcelos VCA and Sasse AD: Abstract P4-12-06: Cost-effectiveness analysis of pertuzumab plus trastuzumab in HER2-positive early breast cancer in Brazil: A public health system perspective. Cancer Res 78 (Suppl 4): P4-12-06, 2018.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.